Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study

被引：0
|
作者：
Lange, T. J. [1 ]
Escribano, P. [2 ]
Biedermann, P. [3 ]
Muller, A. [3 ]
Sun, H. [3 ]
Soderberg, S. [4 ]
Gaine, S. [5 ]
机构：
[1] Univ Klinikum Regensburg, Klin Innere Med 2, Pneumol, Regensburg, Germany
[2] Hosp 12 Octubre, Cibercv, Pulm Hypertens Unit, Cardiol Dept, Madrid, Spain
[3] Actel Pharmaceut Ltd, Malden, MA USA
[4] Umea Univ, Cardiol & Heart Ctr, Dept Publ Hlth & Clin Med, Umea, Sweden
[5] Mater Misericordiae Univ Hosp, Mater Misericordiae Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland
来源：
PNEUMOLOGIE | 2021年 / 75卷
关键词：
D O I：
10.1055/s-0041-1723304
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
FV662
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
    Rosenkranz, S.
    Channick, R.
    Chin, K.
    Jenner, B.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Hoeper, M. M.
    McLaughlin, V
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Sitbon, O.
    Tapson, V
    Lang, I
    PNEUMOLOGIE, 2020, 74 : S62 - S63
  • [32] Selexipag for the Treatment of Schistosomiasis-associated Pulmonary Arterial Hypertension - The SELSCH Study
    Fernandes, C. J.
    Hoette, S.
    Alves, J.
    Salibe-Filho, W.
    Jardim, C.
    Souza, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [33] Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Frey, Aline
    Preiss, Ralph
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Lang, Irene
    McLaughlin, Vallerie
    Rubin, Lewis
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor
    CHEST, 2015, 148 (04)
  • [34] Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
    Sitbon, Olivier
    Channick, Richard
    Chin, Kelly
    Frey, Aline
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    Lang, Irene
    Le Brun, Franck-Olivier
    McLaughlin, Vallerie
    Preiss, Ralph
    Rubin, Lewis J.
    Simonneau, Gerald
    Tapson, Victor
    Gaine, Sean
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [35] COST-EFFECTIVENESS ANALYSIS OF SELEXIPAG VERSUS INHALED ILOPROST IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SWEDEN
    Wlodarczyk, J.
    Hunsche, E.
    Silberberg, B.
    Kemp, D.
    Anell, B.
    Corcoran, K.
    Minacori, R.
    Stevenson, M.
    Beaudet, A.
    VALUE IN HEALTH, 2016, 19 (07) : A556 - A556
  • [36] Clinical Characteristics and Therapy Patterns in Adult Patients with Congenital Heart Disease (CHD) and Pulmonary Arterial Hypertension (PAH) in the US and Japan
    Hirose, Naoki
    Chung, Hsingwen
    Qiu, Hong
    Hayashi, Yasuhiro
    Omura, Junichi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 216 - 217
  • [37] Clinical Improvement in Pulmonary Arterial Hypertension (PAH) Patients Transitioning from Selexipag to Oral Treprostinil: Interim Results from the ADAPT Registry
    Lachant, D.
    Minkin, R.
    Swisher, J.
    Mogri, M.
    Zolty, R.
    Shelton, D.
    Seaman, S.
    Broderick, M.
    Sahay, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [38] The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
    Rosenkranz, Stephan
    Channick, Richard
    Chin, Kelly M.
    Jenner, Bartosz
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    McLaughlin, Vallerie V.
    Du Roure, Camille
    Rubin, Lewis J.
    Sitbon, Olivier
    Tapson, Victor
    Lang, Irene M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (01) : 205 - 214
  • [39] Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE
    Gaine, Sean
    Escribano-Subias, Pilar
    Muller, Audrey
    Fernandes, Catarina C.
    Fontana, Martina
    Remenova, Tatiana
    Soderberg, Stefan
    Lange, Tobias J.
    PULMONARY CIRCULATION, 2024, 14 (03)
  • [40] Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
    Hardin, Elizabeth Ashley
    Chin, Kelly M.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3747 - 3754
12345